This article reviews the literature on SARS-CoV-2 pandemic and multiple sclerosis (MS). The first part of the paper focuses on the current data on immunopathology of SARS-CoV-2 and leading vaccines produced against COVID-19 infection. In the second part of the article, we discuss the effect of Disease Modifying Therapies (DMTs) on COVID-19 infection severity or SARS-CoV-2 vaccination in MS patients plus safety profile of different vaccine platforms in MS patients.

Institute of Immunology and Microbiology Faculty of Medicine Charles University 128 00 Prague Czech Republic

Zobrazit více v PubMed

Alam T., Qamar S. Coronavirus Disease (COVID-19): Reviews, Applications, and Current Status. J. Inform. Univ. Pamulang. 2020;5:213–219. doi: 10.32493/informatika.v5i3.6563. DOI

Garosi V.H., Tanhaie S., Chaboksavar F., Kamari T., Gheshlaghi P.A., Toghroli R., Soltaninezhad S., Azizi S.A., Yazdani V., Mahmoodi F. An overview of 2019 novel coronavirus COVID-19 pandemic: A review study. J. Educ Health Promot. 2021;10:280. PubMed PMC

Shi Y., Wang G., Cai X.P., Deng J.W., Zheng L., Zhu H.H., Zheng M., Yang B., Chen Z. An overview of COVID-19. J. Zhejiang Univ. Sci. B. 2020;21:343–360. doi: 10.1631/jzus.B2000083. PubMed DOI PMC

Singhal T. A Review of Coronavirus Disease-2019 (COVID-19) Indian J. Pediatr. 2020;87:281–286. doi: 10.1007/s12098-020-03263-6. PubMed DOI PMC

Coronavirus Worldometers [Internet] 2022. [(accessed on 1 February 2022)]. Available online: https://www.worldometers.info/coronavirus/

WHO WHO Coronavirus (COVID-19) Dashboard 2022. [(accessed on 1 February 2022)]. Available online: https://covid19.who.int/

WHO Estimating Mortality from COVID-19 2020. [(accessed on 1 February 2022)]. Available online: https://www.who.int/news-room/commentaries/detail/estimating-mortality-from-covid-19.

Ioannidis J.P.A. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bull. World Health Organ. 2021;99:19F–33F. doi: 10.2471/BLT.20.265892. PubMed DOI PMC

Dos Santos W.G. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. Biomed. Pharmacother. 2021;136:111272. doi: 10.1016/j.biopha.2021.111272. PubMed DOI PMC

Shanmugaraj B., Siriwattananon K., Wangkanont K., Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19) Asian Pac. J. Allergy Immunol. 2020;38:10–18. doi: 10.12932/ap-200220-0773. PubMed DOI

Anand U., Jakhmola S., Indari O., Jha H.C., Chen Z.S., Tripathi V., de la Lastra J.M.P. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. Front. Immunol. 2021;12:658519. doi: 10.3389/fimmu.2021.658519. PubMed DOI PMC

Xiao K., Zhai J., Feng Y., Zhou N., Zhang X., Zou J.J., Li N., Guo Y., Li X., Shen X., et al. Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. Nature. 2020;583:286–289. doi: 10.1038/s41586-020-2313-x. PubMed DOI

Li L., Wang X., Hua Y., Liu P., Zhou J., Chen J., An F., Hou F., Huang W., Chen J. Epidemiological Study of Betacoronaviruses in Captive Malayan Pangolins. Front. Microbiol. 2021;12:657439. doi: 10.3389/fmicb.2021.657439. PubMed DOI PMC

Hatmi Z.N. A Systematic Review of Systematic Reviews on the COVID-19 Pandemic. SN Compr. Clin. Med. 2021;3:419–436. doi: 10.1007/s42399-021-00749-y. PubMed DOI PMC

Ahmad S., Hafeez A., Siddqui S.A., Ahmad M., Mishra S. A Review of COVID-19 (Coronavirus Disease-2019) Diagnosis, Treatments and Prevention. Eur. J. Med. Oncol. 2020;4:116–125. doi: 10.14744/ejmo.2020.90853. DOI

Pascarella G., Strumia A., Piliego C., Bruno F., Del Buono R., Costa F., Scarlata S., Agrò F.E. COVID-19 diagnosis and management: A comprehensive review. J. Intern. Med. 2020;288:192–206. doi: 10.1111/joim.13091. PubMed DOI PMC

Ortiz-Prado E., Simbana-Rivera K., Gomez-Barreno L., Rubio-Neira M., Guaman L.P., Kyriakidis N.C., Muslin C., Jaramillo A.M.G., Barba-Ostria C., Cevallos-Robalino D., et al. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect. Dis. 2020;98:115094. doi: 10.1016/j.diagmicrobio.2020.115094. PubMed DOI PMC

Sellner J., Rommer P.S. Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. Vaccines. 2021;9:99. doi: 10.3390/vaccines9020099. PubMed DOI PMC

Su J., Lu H. Opportunities and challenges to the use of neutralizing monoclonal antibody therapies for COVID-19. Biosci. Trends. 2021;15:205–210. doi: 10.5582/bst.2021.01227. PubMed DOI

Harvey W.T., Carabelli A., Jackson B., Gupta R., Thomson E.C., Harrison E.M., Ludden C., Reeve R., Rambaut A., Peacock S., et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 2021;19:409–424. doi: 10.1038/s41579-021-00573-0. PubMed DOI PMC

Baker D., Roberts C.A., Pryce G., Kang A.S., Marta M., Reyes S., Schmierer K., Giovannoni G., Amor S. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin. Exp. Immunol. 2020;202:149–161. doi: 10.1111/cei.13495. PubMed DOI PMC

Sette A., Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861–880. doi: 10.1016/j.cell.2021.01.007. PubMed DOI PMC

Bellucci G., Rinaldi V., Buscarinu M.C., Renie R., Bigi R., Pellicciari G., Morena E., Romano C., Marrone A., Mechelli R., et al. Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started? Front. Immunol. 2021;12:755333. doi: 10.3389/fimmu.2021.755333. PubMed DOI PMC

Kuri-Cervantes L., Pampena M.B., Meng W., Rosenfeld A.M., Ittner C.A.G., Weisman A.R., Agyekum R.S., Mathew D., Baxter A.E., Vella L.A., et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci. Immunol. 2020;5:eabd7114. doi: 10.1126/sciimmunol.abd7114. PubMed DOI PMC

Wolf A., Alvarez E. COVID-19 Vaccination in Patients with Multiple Sclerosis on Disease-Modifying Therapy. Neurol. Clin. Pr. 2021;11:358–361. doi: 10.1212/CPJ.0000000000001088. PubMed DOI PMC

Preziosa P., Rocca M.A., Filippi M. COVID-19 will change MS care forever—No. Mult. Scler. J. 2020;26:1149–1151. doi: 10.1177/1352458520929971. PubMed DOI

Centonze D., Rocca M.A., Gasperini C., Kappos L., Hartung H.P., Magyari M., Oreja-Guevara C., Trojano M., Wiendl H., Filippi M. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: An expert consensus. J. Neurol. 2021;268:3961–3968. doi: 10.1007/s00415-021-10545-2. PubMed DOI PMC

Hughes R., Whitley L., Fitovski K., Schneble H.-M., Muros E., Sauter A., Craveiro L., Dillon P., Bonati U., Jessop N., et al. COVID-19 in ocrelizumab-treated people with multiple sclerosis. Mult. Scler. Relat. Disord. 2021;49:102725. doi: 10.1016/j.msard.2020.102725. PubMed DOI PMC

Hollenbach J.A., Oksenberg J.R. The immunogenetics of multiple sclerosis: A comprehensive review. J. Autoimmun. 2015;64:13–25. doi: 10.1016/j.jaut.2015.06.010. PubMed DOI PMC

Dobson R., Giovannoni G. Multiple sclerosis—A review. Eur. J. Neurol. 2019;26:27–40. doi: 10.1111/ene.13819. PubMed DOI

Hauser S.L., Cree B.A. Treatment of Multiple Sclerosis: A Review. Am. J. Med. 2020;133:1380–1390.e2. doi: 10.1016/j.amjmed.2020.05.049. PubMed DOI PMC

Walton C., King R., Rechtman L., Kaye W., Leray E., Marrie R.A., Robertson N., La Rocca N., Uitdehaag B., Van Der Mei I., et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult. Scler. J. 2020;26:1816–1821. doi: 10.1177/1352458520970841. PubMed DOI PMC

Rachel King P.B., Rijke N., Napier C.A., Walton C., Helme A., Gilbert V., Burr Z., Dobson S. Atlas of MS. 3rd ed. The Multiple Sclerosis International Federation (MSIF); London, UK: 2020. PART 1: Mapping multiple sclerosis around the world key epidemiology findings.

Coyle P.K., Gocke A., Vignos M., Newsome S.D. Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era. Adv. Ther. 2021;38:3550–3588. doi: 10.1007/s12325-021-01761-3. PubMed DOI PMC

Otero-Romero S., Ascherio A., Lebrun-Frénay C. Vaccinations in multiple sclerosis patients receiving disease-modifying drugs. Curr. Opin. Neurol. 2021;34:322–328. doi: 10.1097/WCO.0000000000000929. PubMed DOI

Moiola L., Barcella V., Benatti S., Capobianco M., Capra R., Cinque P., Comi G., Fasolo M.M., Franzetti F., Galli M., et al. The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. Mult. Scler. J. 2021;27:331–346. doi: 10.1177/1352458520952311. PubMed DOI

Winkelmann A., Loebermann M., Reisinger M.L.E.C., Hartung H.-P., Zettl A.W.U.K. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat. Rev. Neurol. 2016;12:217–233. doi: 10.1038/nrneurol.2016.21. PubMed DOI

Maghzi A.H., Houtchens M.K., Preziosa P., Ionete C., Beretich B.D., Stankiewicz J.M., Tauhid S., Cabot A., Berriosmorales I., Schwartz T.H.W., et al. COVID-19 in teriflunomide-treated patients with multiple sclerosis. J. Neurol. 2020;267:2790–2796. doi: 10.1007/s00415-020-09944-8. PubMed DOI PMC

Bollo L., Guerra T., Bavaro D.F., Monno L., Saracino A., Angarano G., Paolicelli D., Trojano M., Iaffaldano P. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide. J. Neurol. Sci. 2020;416:117011. doi: 10.1016/j.jns.2020.117011. PubMed DOI PMC

Ciardi M.R., Zingaropoli M.A., Pasculli P., Perri V., Tartaglia M., Valeri S., Russo G., Conte A., Mastroianni C.M. The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia. J. Neuroimmunol. 2020;346:577323. doi: 10.1016/j.jneuroim.2020.577323. PubMed DOI PMC

Simpson-Yap S., De Brouwer E., Kalincik T., Rijke N., Hillert J.A., Walton C., Edan G., Moreau Y., Spelman T., Geys L., et al. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology. 2021;97:e1870–e1885. doi: 10.1212/WNL.0000000000012753. PubMed DOI PMC

Dersch R., Wehrum T., Fähndrich S., Engelhardt M., Rauer S., Berger B. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment. Mult. Scler. J. 2020;26:1264–1266. doi: 10.1177/1352458520943783. PubMed DOI

Sharifian-Dorche M., Sahraian M.A., Fadda G., Osherov M., Sharifian-Dorche A., Karaminia M., Saveriano A.W., La Piana R., Antel J.P., Giacomini P.S. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review. Mult. Scler. Relat. Disord. 2021;50:102800. doi: 10.1016/j.msard.2021.102800. PubMed DOI PMC

Sormani M.P., Schiavetti I., Carmisciano L., Cordioli C., Filippi M., Radaelli M., Immovilli P., Capobianco M., De Rossi N., Brichetto G., et al. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context. Neurol. Neuroimmunol. Neuroinflamm. 2022;9:e1105. doi: 10.1212/NXI.0000000000001105. PubMed DOI PMC

Kyriakidis N.C., Lopez-Cortes A., Gonzalez E.V., Grimaldos A.B., Prado E.O. SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6:28. doi: 10.1038/s41541-021-00292-w. PubMed DOI PMC

Hodgson S.H., Mansatta K., Mallett G., Harris V., Emary K.R.W., Pollard A.J. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect. Dis. 2021;21:e26–e35. doi: 10.1016/S1473-3099(20)30773-8. PubMed DOI PMC

Pascual-Iglesias A., Canton J., Ortega-Prieto A.M., Jimenez-Guardeno J.M., Regla-Nava J.A. An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era. Pathogens. 2021;10:1030. doi: 10.3390/pathogens10081030. PubMed DOI PMC

Zabalza A., Cárdenas-Robledo S., Tagliani P., Arrambide G., Otero-Romero S., Carbonell-Mirabent P., Rodriguez-Barranco M., Rodríguez-Acevedo B., Vera J.L.R., Resina-Salles M., et al. COVID-19 in multiple sclerosis patients: Susceptibility, severity risk factors and serological response. Eur. J. Neurol. 2021;28:3384–3395. doi: 10.1111/ene.14690. PubMed DOI

Cabreira V., Abreu P., Soares-Dos-Reis R., Guimarães J., Sá M. Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations. Vaccines. 2021;9:773. doi: 10.3390/vaccines9070773. PubMed DOI PMC

Giovannoni G., Hawkes C., Lechner-Scott J., Levy M., Waubant E., Gold J. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult. Scler. Relat. Disord. 2020;39:102073. doi: 10.1016/j.msard.2020.102073. PubMed DOI PMC

Tasat D.R., Yakisich J.S. Rationale for the use of sphingosine analogues in COVID-19 patients. Clin. Med. 2021;21:e84–e87. doi: 10.7861/clinmed.2020-0309. PubMed DOI PMC

Capone F., Motolese F., Luce T., Rossi M., Magliozzi A., Di Lazzaro V. COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review. Mult. Scler. Relat. Disord. 2021;48:102734. doi: 10.1016/j.msard.2020.102734. PubMed DOI PMC

Mantero V., Abate L., Salmaggi A., Cordano C. Multiple sclerosis and COVID-19: How could therapeutic scenarios change during the pandemic? J. Med. Virol. 2021;93:1847–1849. doi: 10.1002/jmv.26796. PubMed DOI PMC

Mares J., Hartung H.-P. Multiple sclerosis and COVID-19. Biomed. Pap. 2020;164:217–225. doi: 10.5507/bp.2020.033. PubMed DOI

Barzegar M., Mirmosayyeb O., Gajarzadeh M., Afshari-Safavi A., Nehzat N., Vaheb S., Shaygannejad V., Maghzi A.H. COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review. Neurol. Neuroimmunol. Neuroinflamm. 2021;8:e1001. doi: 10.1212/NXI.0000000000001001. PubMed DOI PMC

Sormani M.P., De Rossi N., Schiavetti I., Carmisciano L., Cordioli C., Moiola L., Radaelli M., Immovilli P., Capobianco M., Trojano M., et al. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann. Neurol. 2021;89:780–789. doi: 10.1002/ana.26028. PubMed DOI PMC

Giovannoni G., Hawkes C.H., Lechner-Scott J., Levy M., Yeh E.A., Baker D. COVID-19 vaccines and multiple sclerosis disease-modifying therapies. Mult. Scler. Relat. Disord. 2021;53 doi: 10.1016/j.msard.2021.103155. PubMed DOI PMC

Mado H., Adamczyk-Sowa M. Multiple sclerosis patients and COVID-19. Egypt. J. Neurol. Psychiatry Neurosurg. 2021;57:43. doi: 10.1186/s41983-021-00287-3. PubMed DOI PMC

Mantero V., Baroncini D., Balgera R., Guaschino C., Basilico P., Annovazzi P., Zaffaroni M., Salmaggi A., Cordano C. Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis. J. Neurol. 2021;268:2029–2030. doi: 10.1007/s00415-020-10196-9. PubMed DOI PMC

Möhn N., Pul R., Kleinschnitz C., Prüss H., Witte T., Stangel M., Skripuletz T. Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients—Lessons Learned From SARS and MERS. Front. Immunol. 2020;11:1059. doi: 10.3389/fimmu.2020.01059. PubMed DOI PMC

Kulikowska J., Kulczyńska-Przybik A., Mroczko B., Kułakowska A. The Significance of COVID-19 Immunological Status in Severe Neurological Complications and Multiple Sclerosis—A Literature Review. Int. J. Mol. Sci. 2021;22:5894. doi: 10.3390/ijms22115894. PubMed DOI PMC

Gelibter S., Orrico M., Filippi M., Moiola L. COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program? Mult. Scler. Relat. Disord. 2021;49:102775. doi: 10.1016/j.msard.2021.102775. PubMed DOI PMC

De Angelis M., Petracca M., Lanzillo R., Brescia Morra V., Moccia M. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice. Mult. Scler. Relat. Disord. 2020;45:102452. doi: 10.1016/j.msard.2020.102452. PubMed DOI PMC

Preziosa P., Rocca M.A., Nozzolillo A., Moiola L., Filippi M. COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: A monocentric experience. J. Neurol. 2021;268:2697–2699. doi: 10.1007/s00415-020-10309-4. PubMed DOI PMC

Jack D., Nolting A., Galazka A. Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets. Mult. Scler. Relat. Disord. 2020;46:102469. doi: 10.1016/j.msard.2020.102469. PubMed DOI PMC

Celius E.G. Normal antibody response after COVID-19 during treatment with cladribine. Mult. Scler. Relat. Disord. 2020;46:102476. doi: 10.1016/j.msard.2020.102476. PubMed DOI PMC

Flores-Gonzalez R.E., Hernandez J., Tornes L., Rammohan K., Delgado S. Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab. Mult. Scler. Relat. Disord. 2021;49:102777. doi: 10.1016/j.msard.2021.102777. PubMed DOI PMC

MarraMS A.R., Kobayashi T., Suzuki H., Alsuhaibani M., Tofaneto B.M., Bariani L.M., Auler M.d.A., Salinas J.L., Edmond M.B., Doll M., et al. Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis. J. Infect. 2021. Online ahead of print . PubMed DOI PMC

Galmiche S., Nguyen L.B.L., Tartour E., de Lamballerie X., Wittkop L., Loubet P., Launay O. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: A systematic review. Clin. Microbiol. Infect. 2021;28:163–177. doi: 10.1016/j.cmi.2021.09.036. PubMed DOI PMC

Ciotti J.R., Valtcheva M.V., Cross A.H. Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult. Scler. Relat. Disord. 2020;45:102439. doi: 10.1016/j.msard.2020.102439. PubMed DOI PMC

Tazza F., Lapucci C., Cellerino M., Boffa G., Novi G., Poire I., Mancuso E., Bruschi N., Sbragia E., Laroni A., et al. Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? J. Neurol. Sci. 2021;427:117501. doi: 10.1016/j.jns.2021.117501. PubMed DOI PMC

Negahdaripour M., Shafiekhani M., Moezzi S.M.I., Amiri S., Rasekh S., Bagheri A., Mosaddeghi P., Vazin A. Administration of COVID-19 Vaccines in ImmunocompromisedPatients. Int. Immunopharmacol. 2021;99:108021. doi: 10.1016/j.intimp.2021.108021. PubMed DOI PMC

Disanto G., Sacco R., Bernasconi E., Martinetti G., Keller F., Gobbi C., Zecca C. Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis. JAMA Neurol. 2021;78:1529–1531. doi: 10.1001/jamaneurol.2021.3609. PubMed DOI PMC

Herishanu Y., Rahav G., Levi S., Braester A., Itchaki G., Bairey O., Dally N., Shvidel L., Ziv-Baran T., Polliack A., et al. Efficacy of a Third BNT162b2 mRNA COVID-19 Vaccine Dose in Patients with CLL who Failed Standard Two-dose Vaccination. Blood. 2021;139:678–685. doi: 10.1182/blood.2021014085. PubMed DOI PMC

Konig M., Torgauten H.M., Tran T.T., Holmoy T., Vaage J.T., Lund-Johansen F., Nygaard G.O. Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination. JAMA Neurol. 2022;24:215109. doi: 10.1001/jamaneurol.2021.5109. PubMed DOI PMC

Connolly C.M., Teles M., Frey S., Boyarsky B.J., Alejo J.L., Werbel W.A., Albayda J., Christopher-Stine L., Garonzik-Wang J., Segev D.L., et al. Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: A case series. Ann. Rheum Dis. 2022;81:291–293. doi: 10.1136/annrheumdis-2021-221206. PubMed DOI PMC

Jespers V.L.R., Hulstaert F., Wyndham Thomas C., Van Montfort T., Van Damme P., Dogné J.M., Soentjens P., Ramaekers D. Rapid Review of the Evidence on a COVID-19 Booster dose after a Primary Vaccination Schedule. 2021. [(accessed on 27 January 2022)]. Available online: https://kce.fgov.be/sites/default/files/atoms/files/Third%20Covid-19%20vaccination_Report_DUTCH.pdf.

Shapiro L.C., Thakkar A., Campbell S.T., Forest S.K., Pradhan K., Gonzalez-Lugo J.D., Quinn R., Bhagat T.D., Choudhary G.S., McCort M., et al. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell. 2021;40:3–5. doi: 10.1016/j.ccell.2021.11.006. PubMed DOI PMC

Marlet J., Gatault P., Maakaroun Z., Longuet H., Stefic K., Handala L., Eymieux S., Gyan E., Dartigeas C., Gaudy-Graffin C. Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia. Vaccines. 2021;9:1055. doi: 10.3390/vaccines9101055. PubMed DOI PMC

Ahaley S. An Investigation of Three SARS-CoV-2 mRNA doses in Multiple Sclerosis Vaccine Non-Responders 2021. [(accessed on 27 January 2022)]. Available online: https://www.news-medical.net/news/20211020/An-investigation-of-three-SARS-CoV-2-mRNA-doses-in-multiple-sclerosis-vaccine-non-responders.aspx.

Werbel W.A., Boyarsky B.J., Ou M.T., Massie A.B., Tobian A.A.R., Garonzik-Wang J.M., Segev D.L. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Ann. Intern. Med. 2021;174:1330–1332. doi: 10.7326/L21-0282. PubMed DOI PMC

Guerrieri S., Lazzarin S., Zanetta C., Nozzolillo A., Filippi M., Moiola L. Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: An initial real-life experience. J. Neurol. 2021;269:39–43. PubMed PMC

Apostolidis S.A., Kakara M., Painter M.M., Goel R.R., Mathew D., Lenzi K., Rezk A., Patterson K.R., Espinoza D.A., Kadri J.C., et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat. Med. 2021;27:1990–2001. doi: 10.1038/s41591-021-01507-2. PubMed DOI PMC

Moor M.B., Suter-Riniker F., Horn M.P., Aeberli D., Amsler J., Moller B., Njue L.M., Medri C., Angelillo-Scherrer A., Borradori L., et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): An investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021;3:e789–e797. doi: 10.1016/S2665-9913(21)00251-4. PubMed DOI PMC

Tallantyre E.C.V.N., Anderson V., Asardag A.N., Baker D., Bestwick J., Bramhall K., Chance R., Evangelou N., George K., Giovannoni G., et al. COVID-19 vaccine response in people with multiple sclerosis. medRxiv. 2021;91:89–100. doi: 10.1002/ana.26251. PubMed DOI PMC

Gallo A., Capuano R., Donnarumma G., Bisecco A., Grimaldi E., Conte M., D’Ambrosio A., Galdiero M., Tedeschi G. Preliminary evidence of blunted humoral response to SARS-Cov-2 (MRNA) vaccine in multiple sclerosis patients treated with ocrelizumab. J. Neurol. Sci. 2021;429:3523–3526. doi: 10.1007/s10072-021-05397-7. PubMed DOI PMC

Buttari F., Bruno A., Dolcetti E., Azzolini F., Bellantonio P., Centonze D., Fantozzi R. COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab. Mult. Scler. Relat. Disord. 2021;52:102983. doi: 10.1016/j.msard.2021.102983. PubMed DOI PMC

Etemadifar M., Sigari A.A., Sedaghat N., Salari M., Nouri H. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient. Hum. Vaccines Immunother. 2021;17:3481–3483. doi: 10.1080/21645515.2021.1928463. PubMed DOI PMC

Achiron A., Mandel M., Dreyer-Alster S., Harari G., Magalashvili D., Sonis P., Dolev M., Menascu S., Flechter S., Falb R., et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther. Adv. Neurol. Disord. 2021;14:17562864211012835. doi: 10.1177/17562864211012835. PubMed DOI PMC

Capuano R., Donnarumma G., Bisecco A., Grimaldi E., Conte M., d’Ambrosio A., Matrone F., Risi M., Borgo R.M., Altieri M., et al. Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab. Ther. Adv. Neurol. Disord. 2021;14:17562864211038111. doi: 10.1177/17562864211038111. PubMed DOI PMC

Bigaut K., Kremer L., Fleury M., Lanotte L., Collongues N., de Seze J. Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection. Rev. Neurol. 2021;177:1237–1240. doi: 10.1016/j.neurol.2021.05.001. PubMed DOI PMC

Katz J., Bouley A., Lathi E., Douglas E., Jungquist R.M., O’Shea I. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab. Mult. Scler. J. 2021;27:786–787. doi: 10.1016/j.msard.2021.103382. PubMed DOI PMC

Conte W.L. Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: A case-control study. Mult. Scler. Relat. Disord. 2021;52:103014. doi: 10.1016/j.msard.2021.103014. PubMed DOI PMC

Michiels Y., Houhou-Fidouh N., Collin G., Berger J., Kohli E. Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient. Vaccines. 2021;9:1140. doi: 10.3390/vaccines9101140. PubMed DOI PMC

Kelly H., Sokola B., Abboud H. Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. J. Neuroimmunol. 2021;356:577599. doi: 10.1016/j.jneuroim.2021.577599. PubMed DOI PMC

Furlan A., Forner G., Cipriani L., Vian E., Rigoli R., Gherlinzoni F., Scotton P. COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge. Front. Immunol. 2021;12 doi: 10.3389/fimmu.2021.763412. PubMed DOI PMC

Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389. PubMed DOI PMC

Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. PubMed DOI PMC

Lotan I., Wilf-Yarkoni A., Friedman Y., Stiebel-Kalish H., Steiner I., Hellmann M.A. Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel. Eur. J. Neurol. 2021;28:3742–3748. doi: 10.1111/ene.15028. PubMed DOI PMC

Sadoff J., Le Gars M., Shukarev G., Heerwegh D., Truyers C., de Groot A.M., Stoop J., Tete S., Van Damme W., Leroux-Roels I., et al. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. N. Engl. J. Med. 2021;384:1824–1835. doi: 10.1056/NEJMoa2034201. PubMed DOI PMC

Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2, an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1. PubMed DOI PMC

Cattaneo M. Thrombosis with Thrombocytopenia Syndrome associated with viral vector COVID-19 vaccines. Eur. J. Intern. Med. 2021;89:22–24. doi: 10.1016/j.ejim.2021.05.031. PubMed DOI PMC

Chatterjee R., Ghosh M., Sahoo S., Padhi S., Misra N., Raina V., Suar M., Son Y.-O. Next-Generation Bioinformatics Approaches and Resources for Coronavirus Vaccine Discovery and Development—A Perspective Review. Vaccines. 2021;9:812. doi: 10.3390/vaccines9080812. PubMed DOI PMC

Tebas P., Yang S., Boyer J.D., Reuschel E.L., Patel A., Christensen-Quick A., Andrade V.M., Morrow M.P., Kraynyak K., Agnes J., et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine. 2021;31:100689. doi: 10.1016/j.eclinm.2020.100689. PubMed DOI PMC

Xia S., Zhang Y., Wang Y., Wang H., Yang Y., Gao G.F., Tan W., Wu G., Xu M., Lou Z., et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect. Dis. 2021;21:39–51. doi: 10.1016/S1473-3099(20)30831-8. PubMed DOI PMC

Summary of Safety and Efficacy of COVID Vaccination in Patients with Multiple Sclerosis